GlassScriptPhysician profile
Daniel Lee Delo
NPI 1114128618
$5,122.02
in general payments reported to CMS, 2019-2025
26 companies · $890 in 2025
The $890 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $541 · 2020: $237 · 2021: $959 · 2022: $44.06 · 2023: $2,004 · 2024: $447 · 2025: $890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,055 · Travel and Lodging: $1,231 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,055.10 |
| Travel and Lodging | $1,230.66 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,606.89 | 2023 | |
| Amgen INC. | $755.71 | 2019-2025 | Otezla, Tavneos, Krystexxa |
| Abbvie INC. | $401.99 | 2019-2025 | Rinvoq |
| Janssen Biotech, INC. | $287.33 | 2019-2025 | Tremfya, Remicade, Simponi Aria |
| Astrazeneca Pharmaceuticals LP | $272.12 | 2021-2025 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $255.42 | 2019-2024 | Cyltezo |
| Genentech USA, INC. | $238.29 | 2019-2025 | Actemra |
| Ucb, INC. | $185.24 | 2019-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $149.43 | 2019-2025 | Orencia |
| Radius Health, INC. | $146.56 | 2020-2025 | Tymlos |
| Glaxosmithkline, LLC. | $125.29 | 2020-2021 | |
| Lilly USA, LLC | $104.36 | 2021-2025 | Taltz, Zepbound, Olumiant |
| Novartis Pharmaceuticals Corporation | $100.59 | 2019-2025 | |
| Pfizer INC. | $65.71 | 2019-2023 | |
| Fresenius Kabi USA, LLC | $64.69 | 2023-2025 | Idacio |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $53.44 | 2021-2024 | Lupkynis |
| Actelion Pharmaceuticals US, INC. | $48.15 | 2023-2025 | Uptravi, Opsumit |
| Regeneron Healthcare Solutions, INC. | $47.29 | 2019-2020 | |
| Horizon Therapeutics Plc | $46.90 | 2020-2021 | |
| Organon LLC | $40.50 | 2023-2025 | Hadlima |
| Sandoz INC. | $39.95 | 2023-2024 | Hyrimoz |
| Mallinckrodt Hospital Products INC. | $19.96 | 2021 | |
| Sobi, INC | $18.78 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $18.01 | 2021 | |
| Bioventus LLC | $16.27 | 2019 | |
| Celgene Corporation | $13.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Delo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.